S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
New CBOE “special perk” helps traders target income every weekend (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company

Henry Schein Stock Price, News & Analysis (NASDAQ:HSIC)

$71.91
+0.37 (+0.52%)
(As of 12/8/2023 ET)
Compare
Today's Range
$71.50
$72.31
50-Day Range
$61.89
$74.36
52-Week Range
$60.01
$89.72
Volume
1.14 million shs
Average Volume
1.33 million shs
Market Capitalization
$9.34 billion
P/E Ratio
21.40
Dividend Yield
N/A
Price Target
$79.38

Henry Schein MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
10.4% Upside
$79.38 Price Target
Short Interest
Healthy
2.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.43mentions of Henry Schein in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
12.69%
From $4.57 to $5.15 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

146th out of 942 stocks

Medical & Hospital Equipment Industry

2nd out of 3 stocks


HSIC stock logo

About Henry Schein Stock (NASDAQ:HSIC)

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

HSIC Stock Price History

HSIC Stock News Headlines

Goldman Sachs Keeps Their Hold Rating on Henry Schein (HSIC)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Henry Schein (NASDAQ:HSIC) Cut to Hold at StockNews.com
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Is Henry Schein (HSIC) a Good Investment Opportunity?
These Analysts Slash Their Forecasts On Henry Schein After Q3 Results
What 5 Analyst Ratings Have To Say About Henry Schein
Q3 2023 Henry Schein Inc Earnings Call
See More Headlines
Receive HSIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Henry Schein and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/15/2024

Industry, Sector and Symbol

Industry
Medical Distribution
Sub-Industry
Health Care Distributors
Sector
Medical
Current Symbol
NASDAQ:HSIC
CUSIP
80640710
Employees
24,000
Year Founded
1932

Price Target and Rating

Average Stock Price Target
$79.38
High Stock Price Target
$96.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+10.4%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$538 million
Pretax Margin
4.66%

Debt

Sales & Book Value

Annual Sales
$12.69 billion
Cash Flow
$6.68 per share
Book Value
$30.21 per share

Miscellaneous

Free Float
129,096,000
Market Cap
$9.34 billion
Optionable
Optionable
Beta
0.84

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














HSIC Stock Analysis - Frequently Asked Questions

Should I buy or sell Henry Schein stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HSIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HSIC, but not buy additional shares or sell existing shares.
View HSIC analyst ratings
or view top-rated stocks.

What is Henry Schein's stock price target for 2024?

7 equities research analysts have issued 12 month target prices for Henry Schein's stock. Their HSIC share price targets range from $65.00 to $96.00. On average, they predict the company's stock price to reach $79.38 in the next twelve months. This suggests a possible upside of 10.4% from the stock's current price.
View analysts price targets for HSIC
or view top-rated stocks among Wall Street analysts.

How have HSIC shares performed in 2023?

Henry Schein's stock was trading at $79.87 at the beginning of 2023. Since then, HSIC stock has decreased by 10.0% and is now trading at $71.91.
View the best growth stocks for 2023 here
.

Are investors shorting Henry Schein?

Henry Schein saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,460,000 shares, an increase of 39.0% from the October 31st total of 2,490,000 shares. Based on an average daily volume of 996,600 shares, the short-interest ratio is presently 3.5 days. Approximately 2.7% of the shares of the stock are sold short.
View Henry Schein's Short Interest
.

When is Henry Schein's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our HSIC earnings forecast
.

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) announced its quarterly earnings results on Monday, November, 13th. The company reported $1.32 EPS for the quarter, hitting analysts' consensus estimates of $1.32. The firm had revenue of $3.16 billion for the quarter, compared to analyst estimates of $3.21 billion. Henry Schein had a net margin of 3.51% and a trailing twelve-month return on equity of 16.08%. Henry Schein's quarterly revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm posted $1.15 earnings per share.
Read the conference call transcript
.

When did Henry Schein's stock split?

Henry Schein shares split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were distributed to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein declared that its Board of Directors has approved a share buyback program on Thursday, August 18th 2022, which permits the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 4% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company's board of directors believes its shares are undervalued.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein updated its FY23 earnings guidance on Monday, November, 13th. The company provided earnings per share guidance of $4.43-4.71 for the period, compared to the consensus estimate of $5.20. The company issued revenue guidance of down 1-3% yr/yr to ~$12.27-12.52 billion, compared to the consensus revenue estimate of $12.83 billion.

What is Stanley M. Bergman's approval rating as Henry Schein's CEO?

451 employees have rated Henry Schein Chief Executive Officer Stanley M. Bergman on Glassdoor.com. Stanley M. Bergman has an approval rating of 94% among the company's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

Who are Henry Schein's major shareholders?

Henry Schein's stock is owned by many different institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (3.65%), American Century Companies Inc. (3.61%), Invesco Ltd. (3.36%), Perpetual Ltd (3.28%), Morgan Stanley (1.62%) and Massachusetts Financial Services Co. MA (1.32%). Insiders that own company stock include Bradford C Connett, David B Brous Jr, Deborah Derby, Gerald A Benjamin, James P Breslawski, James P Breslawski, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael S Ettinger, Philip A Laskawy, Scott Philip Serota, Stanley M Bergman, Steven Paladino and Walter Siegel.
View institutional ownership trends
.

How do I buy shares of Henry Schein?

Shares of HSIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Henry Schein have any subsidiaries?
The following companies are subsidiares of Henry Schein: ACE Surgical Supply Co. Inc., ADS Florida, AUV Veterinary Services, Accord, Alpha Scientific, Arcade Dentaire, Arseus, Arseus Dental Solutions, Arseus Lab, Becker-Parkin Dental Supply, BioHorizons Inc., Butler Schein Animal Health, C&M Vetlink, Camlog USA Inc., DNA Anthos Impianti, Dental Cremer, Dental Trey, Elite Computer Italia, Exan Enterprises Inc., HS Brand Management LLC, HS TM Holdings LLC, HSFR Inc., Handpiece Parts & Repairs Inc., Henry Schein Europe Inc., Henry Schein Global Sourcing Inc., Henry Schein Latin America Pacific Rim Inc., Henry Schein Medical Systems Inc., Henry Schein Practice Solutions Inc., InSource Inc., Jorgen Kruuse, Lincoln Dental Supply, Logiciel Julie, Maddox Practice Group, Maravet, Marrodent, Medivet, Medka, Minerva Dental Limited, Modern Laboratory Services, NLS Animal Health, Noviko, Ortho Organizers, Ortho Technology, Prism Medical Products L.L.C., Prism Medical Products LLC, Project Helium Holdings LLC, Project Spartan Holdings Corp., RxWorks, SG Healthcare Corp., Sirona Direct, SmartPak Equine LLC, Software of Excellence, Sogim Grimouille, Southern Anesthesia & Surgical, S & S Discount Inc., TDSC Inc., The Exan Group, Veterinary Instrumentation, Vetstreet, W. & J. Dunlop, eAssist Inc., and scil animal care.
Read More
This page (NASDAQ:HSIC) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -